Oral nanomedicine approaches for the treatment of psychiatric illnesses
- 1 February 2016
- journal article
- review article
- Published by Elsevier in Journal of Controlled Release
- Vol. 223, 137-156
Abstract
No abstract availableKeywords
Funding Information
- Australian Research Council (DP120101065)
- Itek Pty. Ltd.
- Bioinnovation South Australia
- Australian Biotech Ceridia Pty. Ltd.
This publication has 157 references indexed in Scilit:
- A novel preparation method for drug nanocrystals and characterization by ultrasonic spray assisted electrostatic adsorptionInternational Journal of Nanomedicine, 2013
- In vitro and in vivo models for the study of oral delivery of nanoparticlesAdvanced Drug Delivery Reviews, 2013
- Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugsAdvanced Drug Delivery Reviews, 2012
- Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug deliveryAdvanced Drug Delivery Reviews, 2012
- A new fluoride mediated synthesis of mesoporous silica and their usefulness in controlled delivery of duloxetine hydrochloride a serotonin re-uptake inhibitorJournal of Industrial and Engineering Chemistry, 2012
- Brain delivery of olanzapine by intranasal administration of transfersomal vesiclesJournal of Liposome Research, 2012
- Duloxetine HCl Lipid Nanoparticles: Preparation, Characterization, and Dosage Form DesignAAPS PharmSciTech, 2011
- Development of stealth liposome coencapsulating doxorubicin and fluoxetineJournal of Liposome Research, 2011
- Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug DeliveryAAPS PharmSciTech, 2010
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005